Original Article

Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting

Authors: Win Oo, MD, Andrzej Kozikowski, PhD, Joanna Stein, MPH, James Lolis, MD, Renee Pekmezaris, PhD, Amgad N. Makaryus, MD, Gisele Wolf-Klein, MD

Abstract

Objectives: To explore physician practice patterns with regard to antithrombotic therapy, including antiplatelets and anticoagulants, in long-term care residents and compare resulting embolic complications.

Methods: Conducted between August 2012 and March 2013, this study was a retrospective chart review of 400 residents of a long-term care facility. Electronic charts from October 2005 through January 2013 were selected using systematic random sampling.

Results: Approximately one-third of residents (29.6%) received anticoagulants, 27.3% received antiplatelets, 15.8% received both, and 27.3% did not receive any antithrombotic therapy. The most commonly prescribed antithrombotic drugs were aspirin (37.5%) and warfarin (22.1%). The type of antithrombotic therapy was significantly associated with medical history, including deep vein thrombosis ( P = 0.03), the presence of atrial fibrillation ( P = 0.001) and other nonsurgical medical conditions ( P = 0.0001). Weight ( P = 0.009) and body mass index ( P = 0.007) also were significantly associated with type of antithrombotic therapy, indicating that heavier residents and those with a higher body mass index were more likely to receive both anticoagulants and antiplatelets. There was no difference in the number of embolic complications among groups.

Conclusions: Physicians are more disposed to initiate and maintain residents on aspirin while being more cautious when prescribing anticoagulants such as warfarin, dabigatran, heparin, and enoxaparin. In some residents, anticoagulants were not used at all, even when residents had particular risk factors, demonstrating that at times physicians may err on the side of overcautiousness. Antithrombotic therapy should be individualized for each resident based on bleeding risk, comorbidities, and benefits of a particular therapy for our most vulnerable populations.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Office of the Surgeon General. Surgeon General’s workshop on deep-vein thrombosis. http://www.ncbi.nlm.nih.gov/books/NBK44178. Accessed June 1, 2015.
 
2. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-1174.
 
3. Kniffin WD Jr, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-86.
 
4. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-372.
 
5. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-453.
 
6. Heit JA, Cohen AT, Anderson FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005;106:910.
 
7. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-1248.
 
8. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-394.
 
9. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358:1037-1052.
 
10. Geske JB, Smith SB, Morgenthaler TI, et al. Care of patients with acute pulmonary emboli: a clinical review with cardiovascular focus. Expert Rev Cardiovasc Therap 2012;10:235-250.
 
11. Torn M, Bollen WL, van der Meer FJ, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005;165:1527-1532.
 
12. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-1116.
 
13. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365: 2002-2012.
 
14. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007;120:539-544.
 
15. Abdel-Latif AK, Peng X, Messinger-Rapport BJ. Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation. J Am Med Dir Assoc 2005;6:128-131.
 
16. Verhovsek M, Motlagh B, Crowther MA, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr 2008;8:13.
 
17. Karki SD, Lander SM. Evaluation of anticoagulation therapy in an academic nursing home. J Pharm Technol 2003;19:141-145.
 
18. Robert-Ebadi H, Righini M. Anticoagulation in the elderly. Pharmaceuticals 2010;3:3543-3569.
 
19. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001;161:2458-2463.
 
20. Pai M, Douketis JD. Preventing venous thromboembolism in long-term care residents: Cautious advice based on limited data. Cleve Clin J Med 2010;77:123-130.
 
21. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94.
 
22. Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157:796-807.
 
23. Pan L, Fergusson D, Schweitzer I, et al. Ensuring high accuracy of data abstracted from patient charts: the use of a standardized medical record as a training tool. J Clin Epidemiol 2005;58:918-923.
 
24. Hess DR. Retrospective studies and chart reviews. Respir Care 2004;49:1171-1174.
 
25. Gearing RE, Mian IA, Barber J, et al. A methodology for conducting retrospective chart review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2006;15:126-134.
 
26. Centers for Medicare & Medicaid Services. Nursing home data compendium, 2013 edition. http://www.cms.gov/Medicare/ProviderEnrollment-and-Certification/CertificationandComplianc/downloads/nursinghomedatacompendium:508.pdf. Accessed March 1, 2015.